$CIENBearishMed

Why Ciena Stock Is Plummeting Today

Ciena shares fell 14.9% to $541.75 as of 2 p.m. ET, while the S&P 500 and Nasdaq rose. The company reported fiscal Q2 2026 results ended May 2: adjusted EPS $1.64 on sales of $1.57B, beating analyst estimates, and raised full-year sales guidance to about $6.3B and adjusted gross margin to 44.5%-45%.

Med
Bearish
Pre-market Q2 results and raised full-year guidance; selloff during Thursday trading.
Contradictory: fundamentals positive (beat/raise) but price action strongly negative.

Despite upside fundamentals (beat + raised guidance), the market is selling CIEN on the magnitude/quality of the guidance reaction.

Ciena’s pre-market Q2 FY2026 results beat expectations and raised full-year guidance, yet the stock is down ~15% intraday.

Bearish near-term bias; expect elevated volatility as investors reassess forward expectations.

Background

Ciena reported fiscal Q2 2026 results (ended May 2) and simultaneously raised full-year sales and adjusted gross margin guidance.

Why it matters

The key trade tension is that reported beats and higher guidance did not prevent a large intraday decline, implying investors may have been focused on forward demand, margin sustainability, or the size of the raise versus expectations.

Market relevance

A single-stock post-earnings reaction: beat + guidance raise paired with a ~15% drop suggests expectations were even higher or forward details disappointed.

Market effects

Could signal tougher sentiment for networking equipment names if investors treat CIEN’s guidance raise as insufficient.

No specific regional driver cited beyond broad index strength.

No direct global macro/geopolitical linkage mentioned.

Alternative perspectives

The guidance raise and large YoY growth could mean the selloff is positioning/expectations-driven rather than a deterioration in fundamentals.

The article doesn’t detail consensus magnitude versus the raised midpoint, backlog/order trends, or margin drivers—those could explain why the market sold despite the beat.

Key entities

  • Ciena

    Networking technologies provider; released Q2 FY2026 results and raised full-year guidance, but shares fell sharply on the day.

Related articles

$CIENMed

Ciena Shares Plunge 19% Despite Strong Q2 Earnings Growth

Ciena’s (CIEN) shares fell 19.29% to $500.78 on Thursday, down $119.59 from the prior close of $620.37, despite strong Q2 results. The company reported net earnings of $218.22 million ($1.49/share) versus $8.96 million ($0.06/share) a year earlier, and adjusted earnings of $240.19 million ($1.64/share). Revenue rose 39.6% to $1.57 billion from $1.13 billion.

$CIENMed

Ciena reports fiscal Q2 earnings beat, shares slide on guidance

Ciena (CIEN) reported fiscal Q2 results for the quarter ended May 2 that beat Wall Street on both earnings and revenue. Adjusted EPS was $1.64 vs $1.46 expected; revenue was $1.57B vs about $1.50B. Optical Networking revenue rose to $1.1B. Despite the beat, shares fell ~19% after guidance concerns. Ciena raised fiscal 2026 revenue to $6.3B (±$100M) and expects Q3 revenue of $1.625B (±$50M) with adjusted gross margin ~45%.

$CRWDMed

Nasdaq stages comeback after Broadcom, Crowdstrike earnings

Nasdaq opened lower as tech earnings disappointed, led by Broadcom’s >14% drop after AI revenue guidance and its 2027 AI target fell short of expectations. CrowdStrike shares fell ~5.4% despite fiscal Q1 results beating estimates and raising outlook; Wedbush reiterated an $720 target. Other movers included UnitedHealth’s upgrade, Pinterest’s $4B AWS deal, and PVH’s ~20% after-hours drop.

$GSMed

Dow industrial average is surging led by financials in healthcare.

The Dow Jones Industrial Average rose about 930 points, or 1.84%, with 25 of 30 components higher and the index on pace for a record close. Financials led, including Goldman Sachs (+4.93%), JPMorgan (+3.64%) and American Express (+4.41%), while healthcare also supported gains such as UnitedHealth (+5.20%) and Merck (+3.73%). Decliners included Verizon (-2.44%) and IBM (-1.10%).

$CIENMed

What’s up with… Ciena, SK Telecom, Foxconn

Ciena reported fiscal Q2 revenue of $1.57bn (+39.5% y/y) and EBITDA of $283.1m (+324.4%), with gross margin rising to 44% and operating margin to 15.1%. It raised its current-quarter revenue outlook to $1.625bn and full-year sales forecast to about $6.3bn, but shares fell 18.3% to $507.25. SK Telecom joined Anthropic’s Project Glasswing; Foxconn partnered with Intel and SK Group on AI infrastructure. SpaceX set IPO terms at $135/share, valuing it at $1.75tn.

$AVGOMed

Futures Slide After Broadcom Forecast Miss Chills Tech Euphoria

US equity futures fell as tech stocks slid after Broadcom’s AI-chip outlook missed expectations. As of 8:00am ET, S&P futures -0.4% and Nasdaq futures -1.2%. Broadcom shares fell about 13–14% premarket; CrowdStrike dropped ~10% after its revenue forecast disappointed. Investors also watched macro data (job cuts, claims) and upcoming earnings.